



Paris, April 23rd, 2010 – For immediate release

Successful IPO of AB Science on NYSE Euronext - Compartment B

- Offering Price: €12.65 per share – Amount raised by the company: €16.5M
- Amount of the offer: approximately €27.5M
- Trading to begin on April 26th, 2010

AB SCIENCE, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), has announced the final terms of its initial public offering on Euronext Paris (Compartment B, ISIN: FR0010557264 – Ticker: AB).

Through this IPO, AB Science has raised over 16.5 million euros, dedicated to pursuing and expanding the scope of the clinical development of its lead compound, masitinib.

Commenting on the results of the initial public offering, Mr. Alain Moussy, Chief Executive Officer of AB Science Group said: *"We are very happy with our company's successful listing, and we want to thank all of the European institutional and individual shareholders who have joined us in this ambitious effort. By listing, we have raised the funds we need to start up new Phase 3 clinical studies for our flagship molecule masitinib in human medicine (multiple myeloma, multiple sclerosis, Alzheimer's disease, rheumatoid arthritis and severe asthma), and thus pursue the mission that has driven us from the start: delivering targeted therapies that can dramatically improve quality of life for patients suffering from cancer, neurodegenerative disorders and inflammatory diseases"*.

GENERAL TERMS OF THE GLOBAL OFFERING

Offering Price

- The offering price for the global offering is €12.65 per share¹.

This price results in a market capitalization for the AB Science Group of approximately €379 million, making the company one of the biggest in the industry in France.

Size of the Offer and gross proceeds of the global offering (not including the Over-Allotment Option)²

- 1,305,700 new shares have been issued and 864,394 existing shares have been sold (including 137,574 for the extension clause)
- The gross proceeds, after partial exercise of the extension clause, totals approximately €27.5M after, of which 16.5 M€ from newly issued shares and approximately 11M€ for the selling shareholders

¹ The indicative initial price range was comprised between €13.95 and €17.05 per share and revised between €12.30 and €13.00.

² Over-allotment option: The number of shares offered may be increased by a maximum of 325,515 supplementary existing shares to be sold, i.e. 15% of the initial offering (including the Extension clause).

Breakdown of the Offering (not including the Over-Allotment Option)

- Global Placement: 1,820,701 shares were placed in the French and international offering (i.e. approximately €23.1 million or 84% of the offered shares).
- Public Offering in France: 349,393 shares were placed in the French public offering (i.e. approximately €4.4 million or 16% of the offered shares).
- For the public Offering, A1 orders are 100% satisfied and A2 orders are 59.7% satisfied.

Offering Timetable

- Trading on Euronext Paris (Compartment B) to begin on April 26th, 2010.
- Settlement and delivery of the shares is expected to take place on April 28th, 2010.
- May 21st, 2010 - Deadline for exercising the Over-allotment option / End of stabilization period

Banking syndicate



SOCIÉTÉ GÉNÉRALE
Corporate & Investment Banking

Société Générale Corporate & Investment Banking is acting as Lead manager and bookrunner.

Fortis Bank Nederland

Fortis Bank Nederland is acting as Joint lead manager.

Financial Communication & Press Relations

Citigate
Dewe Rogerson

Contacts Citigate Dewe Rogerson :

Agnès Villeret - Tel: +33 1 53 32 78 95 - agnes.villeret@citigate.fr

Matthieu Pirouelle - Tel : +33 1 53 32 84 77 - matthieu.pirouelle@citigate.fr

Public information

Copies of the Prospectus are available free of charge from the Company and from the Lead Manager and Bookrunner and the Joint-Lead Manager. The Prospectus may be viewed on the websites of the Company (www.ab-science.com) and the AMF (www.amf-france.org). The legal and financial documents required to be made available to shareholders may be consulted at the registered office of the Company, 3 avenue George V, 75008 Paris. The attention of investors is drawn to Section 4, "Risk Factors", contained in the Document de base registered with the AMF, the update of such Document de base filed with the AMF and to Section 2 "Risk Factors" contained in the Note d'opération.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. Masitinib, a lead compound, has already been registered in veterinary medicine in Europe and is pursuing three on-going phases 3 in human medicine in pancreatic cancer, GIST and mastocytosis.

Further information is available on AB Science's website: www.ab-science.com

Disclaimer

This press release, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such press release in certain jurisdiction may constitute a breach of applicable laws and regulation.

In particular:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any financial instruments in the United States. Securities mentioned in this document have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. Any public offer of securities in the United States shall be made by means of a prospectus that may be obtained from the issuer containing detailed information regarding the Company, its management and financial statements. The Company does not intend to register this offering in all or in part or to make a public offer of securities in the United States.

This press release is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This document is directed only at (i) persons outside the United Kingdom; or (ii) persons in the United Kingdom that are "qualified investors" within the meaning of Article 2(1)(e) of Directive 2003/71/EC including any relevant implementing measure in each member state, that are also (a) persons authorised under FSMA or otherwise having professional experience in matters relating to investments and qualifying as investment professionals under article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order"); or (b) institutions or corporations qualifying as high net worth persons under Article 49(2)(a) to (d) of the Financial Promotion Order; or (c) any other persons to whom this document for the purposes of Section 21 of FSMA can otherwise lawfully be made (all such persons together being referred to as "Relevant Persons"). Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document.

This document contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Prospectus, changes in economic conditions, the financial markets or the markets in which AB Science operates.

Société Générale, acting as stabilizing agent, or any institution acting on its behalf (the "Stabilizing Agent") may, during a period of 30 days following the date on which the offering price is determined, ie, according to the indicative timetable, from April 23 to May 21, 2010, effect transactions with a view to maintaining the market price of AB Science shares in a manner consistent with applicable laws and regulations and, in particular, EU Commission regulation no 2273/03 of December 22, 2003. However, there is no assurance that the Stabilizing Agent will take any stabilizing action and, if begun, such stabilizing action may be interrupted at any time. Any stabilizing action may affect the price of AB Science shares and could result in market prices for the shares higher than those which might otherwise prevail.